BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1567179)

  • 1. Comparison of tumour markers TAG 12 with CA 15-3 and MCA in breast cancer diagnosis.
    Eskelinen M; Hippelainen M; Salmela E; Paajanen H; Carlsson L; Jonsson P; Alhava E
    Anticancer Res; 1992; 12(1):39-42. PubMed ID: 1567179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
    Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
    Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
    Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A decision support system for predicting a recurrence of breast cancer; a prospective study of serum tumour markers TAG 12, CA 15-3 and MCA.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P; Alhava E
    Anticancer Res; 1992; 12(5):1439-42. PubMed ID: 1444204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer?
    Eskelinen M; Pasanen P; Janatuinen E; Pettersson N; Linnane A; Alhava E
    Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new tumor marker MCA in breast cancer diagnosis.
    Eskelinen M; Tikanoja S; Collan Y
    Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M; Tikanoja S; Brown J
    Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of CA 15-3 and MCA monoclonal antibody assays in the detection of primary and recurrent breast cancer.
    Pirolo F; Pacini P; Borsotti M; la Morgia R; Mungai R; Cappellini M; Cardona G; Cataliotti L; Marzano S; Neri B
    Anticancer Res; 1991; 11(2):729-31. PubMed ID: 2064326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
    Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
    Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor markers MCA and CA-125 in the diagnosis and monitoring of breast cancer].
    Shakhtarin VV; Izotova IA; Parshkov EM; Chekin SIu; Simakova GM
    Vopr Onkol; 1992; 38(4):433-9. PubMed ID: 1300737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
    Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient test for cancer antigens: decreased levels of cancer antigen in serum after excision of breast tumor.
    Eskelinen M; Tikanoja S; Collan Y
    Anticancer Res; 1989; 9(2):437-9. PubMed ID: 2751269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCA performance in preoperative breast cancer patients.
    Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
    Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated antigen CA 15-3 in the diagnostics of breast tumours.
    Eskelinen M; Tikanoja S; Valkamo E; Loikkanen M; Collan Y
    Scand J Clin Lab Invest; 1988 Nov; 48(7):653-8. PubMed ID: 3201097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.
    Bray KR; Koda JE; Gaur PK
    Cancer Res; 1987 Nov; 47(22):5853-60. PubMed ID: 2444335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients.
    Cohen AD; Gopas J; Karplus G; Cohen Y
    Isr J Med Sci; 1995; 31(2-3):155-9. PubMed ID: 7744585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of mucinous-like cancer antigen (MCA) in women with breast disease: preliminary results.
    Valenti G; Zanardi S; Valtolina M; Bombardieri E; Boccardo F
    Cancer Detect Prev; 1991; 15(4):285-9. PubMed ID: 1794135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
    Gaspar MJ; De Miguel J; García Díaz JD; Díez M
    Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.